Anand Reddi joined BeiGene in 2023 as Vice President, Global Strategic Initiatives and Chief of Staff to the CEO.

Prior to BeiGene, Mr. Reddi served on the executive committee at Adverum Biotechnologies as Vice President of Corporate Strategy, Corporate Affairs and Investor Relations.  At Gilead Sciences, he held strategy and operations leadership roles in emerging markets, medical affairs, corporate affairs, corporate and global product strategy, and digital innovation.  Mr. Reddi was instrumental in the launch of 12 blockbuster medicines at Gilead benefiting over 25 million patients in 140 countries.  He started his career in basic science, clinical research, and global health policy.

Mr.  Reddi serves on the board of directors of Hepion Pharmaceuticals (NASDAQ:HEPA).  He is a graduate of the University of Michigan and the University of Colorado School of Medicine and was a J. William Fulbright Scholar in South Africa.